Reduction of LDL cholesterol by a monoclonal antibody to PCSK9 in rodents and nonhuman primates

Clinical Lipidology

Volumn 7, Issue 6, 2012, Pages 737-743

  Gusarova, Viktoria ^a   Howard, Victor G ^b   Okamoto, Haruka ^a   Koehler Stec, Ellen Marie ^a   Papadopoulos, Nicholas ^a   Murphy, Andrew J ^a   Yancopoulos, George D ^a   Stahl, Neil ^a   Sleeman, Mark W ^b  

^a REGENERON PHARMACEUTICALS INC   (United States)

^b MONASH UNIVERSITY   (Australia)

Author keywords

cynomolgus monkey; hypercholesterolemia; LDL cholesterol; monoclonal antibody; PCSK9; rodent

Indexed keywords

ALIROCUMAB; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; PROTEIN PCSK9; SUBTILISIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY ISOLATION; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG SCREENING; HAPLORHINI; HYPERLIPIDEMIA; IN VITRO STUDY; LIVER LEVEL; MALE; MOUSE; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; SINGLE DRUG DOSE;

ANIMALIA; MACACA FASCICULARIS; MUS; PRIMATES; RODENTIA;

EID: 84871397660     PISSN: 17584299     EISSN: 17584302     Source Type: Journal    
DOI: 10.2217/clp.12.70     Document Type: Article

References (26)

1. Zhang DW, Lagace TA, Garuti R et al. Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J. Biol Chem. 282(25), 18602-18612 (2007). (Pubitemid 47100234)
2. Abifadel M, Varret M, Rabes JP et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat. Genet. 34(2), 154-156 (2003). (Pubitemid 36666925)
3. Timms KM, Wagner S, Samuels ME et al. A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree. Hum. Genet. 114(4), 349-353 (2004). (Pubitemid 38324948)
4. Cohen J, Pertsemlidis A, Kotowski IK, Graham R, Garcia CK, Hobbs HH. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat. Genet. 37(2), 161-165 (2005).
5. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med. 354(12), 1264-1272 (2006).
6. Zhao Z, Tuakli-Wosornu Y, Lagace TA et al. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am. J. Hum. Genet. 79(3), 514-523 (2006). (Pubitemid 44384260)
7. Hooper AJ, Marais AD, Tanyanyiwa DM, Burnett Jr. The C679X mutation in PCSK9 is present and lowers blood cholesterol in a southern African population. Atherosclerosis 193(2), 445-448 (2007). (Pubitemid 47058112)
8. Valenzuela DM, Murphy AJ, Frendewey D et al. High-throughput engineering of the mouse genome coupled with high-resolution expression analysis. Nat. Biotechnol. 21(6), 652-659 (2003). (Pubitemid 36638092)
9. Poueymirou WT, Auerbach W, Frendewey D et al. F0 generation mice fully derived from gene-targeted embryonic stem cells allowing immediate phenotypic analyses. Nat. Biotechnol. 25(1), 91-99 (2007). (Pubitemid 46091512)
10. Maxwell KN, Soccio RE, Duncan EM, Sehayek E, Breslow JL. Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed mice. J. Lipid Res. 44(11), 2109-2119 (2003). (Pubitemid 37509626)
11. Rashid S, Curtis DE, Garuti R et al. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc. Natl Acad. Sci. USA 102(15), 5374-5379 (2005). (Pubitemid 40530265)
12. Chan JC, Piper DE, Cao Q et al. A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc. Natl Acad. Sci. USA 106(24), 9820-9825 (2009).
13. Ni YG, Di Marco S, Condra JH et al. A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo. J. Lipid Res. 52(1), 78-86 (2011).
14. Liang H, Chaparro-Riggers J, Strop P et al. Proprotein convertase substilisin/kexin type 9 antagonism reduces low-density lipoprotein cholesterol in statin-treated hypercholesterolemic nonhuman primates. J. Pharmacol. Exp. Ther. 340(2), 228-236 (2012).
15. Stein EA, Mellis S, Yancopoulos GD et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N. Engl. J. Med. 366(12), 1108-1118 (2012).
16. McKenney JM, Koren MJ, Kereiakes DJ, Hanotin C, Ferrand AC, Stein EA. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J. Am. Coll. Cardiol. 59(25), 2344-2353 (2012).
17. Stein EA, Gipe D, Bergeron J et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a Phase 2 randomised controlled trial. Lancet 380(9836), 29-36 (2012).
18. Baigent C, Blackwell L, Emberson J et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376(9753), 1670-1681 (2010).
19. Emberson JR, Kearney PM, Blackwell L et al. Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS ONE 7(1), e29849 (2012).
20. Kitkungvan D, Lynn Fillipon NM, Dani SS, Downey BC. Low-density lipoprotein cholesterol target achievement in patients at high risk for coronary heart disease. J. Clin. Lipidol. 4(4), 293-297 (2010).
21. Hsia J, MacFadyen JG, Monyak J, Ridker PM. Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). J. Am. Coll. Cardiol. 57(16), 1666-1675 (2011).
22. Wiviott SD, Cannon CP, Morrow DA, Ray KK, Pfeffer MA, Braunwald E. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy. J. Am. Coll. Cardiol. 46(8), 1411-1416 (2005). (Pubitemid 41446174)
23. LaRosa JC, Grundy SM, Kastelein JJ, Kostis JB, Greten H. Safety and efficacy of atorvastatin-induced very low-density lipoprotein cholesterol levels in patients with coronary heart disease (a post-hoc analysis of the treating to new targets [TNT] study). Am. J. Cardiol. 100(5), 747-752 (2007). (Pubitemid 47271930)
24. Tremblay AJ, Lamarche B, Lemelin V et al. Atorvastatin increases intestinal expression of NPC1L1 in hyperlipidemic men. J. Lipid Res. 52(3), 558-565 (2011).
25. Costet P, Hoffmann MM, Cariou B, Guyomarc'h Delasalle B, Konrad T, Winkler K. Plasma PCSK9 is increased by fenofibrate and atorvastatin in a non-additive fashion in diabetic patients. Atherosclerosis 212(1), 246-251 (2010).
26. Roth EM, McKenney JM, Hanotin C, Asset G, Stein EA. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N. Engl. J. Med. 367(20), 1891-1900 (2012).